We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.51B
AUM Growth
-$254M
Cap. Flow
-$15.3M
Cap. Flow %
-0.61%
Top 10 Hldgs %
28.7%
Holding
145
New
11
Increased
46
Reduced
10
Closed
7

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$25.7M
2
AMGN icon
Amgen
AMGN
+$24.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$19.6M
4
QURE icon
uniQure
QURE
+$11.2M
5
CNC icon
Centene
CNC
+$11.2M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$77.4M
2
BMY icon
Bristol-Myers Squibb
BMY
+$47.6M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$31.8M
4
PRAH
PRA Health Sciences, Inc.
PRAH
+$23.8M
5
A icon
Agilent Technologies
A
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 86.82%
2 Consumer Staples 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TBIO
76
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$10.2M 0.4%
1,025,000
+15,821
+2% +$149K
ZGNX
77
DELISTED
Zogenix, Inc.
ZGNX
$10M 0.4%
250,000
+15,000
+6% +$691K
CNC icon
78
Centene
CNC
$32.5B
$9.94M 0.4%
+229,800
New +$11.2M
BMRN icon
79
BioMarin Pharmaceuticals
BMRN
$12.4B
$9.61M 0.38%
142,500
– –
PHR icon
80
Phreesia
PHR
$773M
$8.75M 0.35%
+361,000
New +$9.52M
DCPH
81
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$8.48M 0.34%
+250,000
New +$7.4M
ANAB icon
82
AnaptysBio
ANAB
$1.68B
$8.4M 0.33%
240,000
+21,500
+10% +$1.02M
FOLD
83
DELISTED
Amicus Therapeutics
FOLD
$8.02M 0.32%
1,000,000
– –
MIRM icon
84
Mirum Pharmaceuticals
MIRM
$6.14B
$7.95M 0.32%
+790,048
New +$9.69M
RIGL icon
85
Rigel Pharmaceuticals
RIGL
$750M
$7.85M 0.31%
420,000
– –
QTTB icon
86
Q32 Bio
QTTB
$464M
$7.69M 0.31%
23,611
– –
QURE icon
87
uniQure
QURE
$3.22B
$7.66M 0.31%
+194,500
New +$11.2M
JNJ icon
88
Johnson & Johnson
JNJ
$625B
$7.25M 0.29%
+56,000
New +$7.38M
ACAD icon
89
Acadia Pharmaceuticals
ACAD
$5.03B
$6.73M 0.27%
+187,000
New +$5.67M
DVAX
90
DELISTED
Dynavax Technologies
DVAX
$6.61M 0.26%
1,850,000
+1,200,000
+185% +$4.65M
RYTM icon
91
Rhythm Pharmaceuticals
RYTM
$7.96B
$6.58M 0.26%
305,000
+70,000
+30% +$1.5M
ELV icon
92
Elevance Health
ELV
$85.5B
$6.48M 0.26%
27,000
+7,000
+35% +$1.92M
PBYI icon
93
Puma Biotechnology
PBYI
$454M
$6.32M 0.25%
587,400
+53,000
+10% +$572K
SYRE icon
94
Spyre Therapeutics
SYRE
$9.25B
$6.15M 0.25%
32,000
– –
PHAS
95
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$5.91M 0.24%
1,416,900
-6,356
-0.4% -$50.7K
KRTX
96
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$5.88M 0.23%
360,400
-53,100
-13% -$1.03M
SPRO icon
97
Spero Therapeutics
SPRO
$73M
$5.57M 0.22%
525,000
– –
SRGA
98
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$5.56M 0.22%
65,000
– –
AXNX
99
DELISTED
Axonics, Inc. Common Stock
AXNX
$5.45M 0.22%
202,500
-197,500
-49% -$6.88M
MNTA
100
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$5.18M 0.21%
400,000
– –
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, Rock Springs Capital Management held 145 positions worth $2.51B, down 9.2% from $2.76B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management's Q3 2019 filing shows 11 new, 46 increased, 10 reduced and 7 closed positions. Its largest new stake was Amgen: 126,000 shares worth $24.4M. The largest sale was GW Pharmaceuticals Plc American Depositary Shares, an estimated $77.4M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 86% a quarter earlier, followed by Consumer Staples.

  • Rock Springs Capital Management's largest Q3 2019 buy was Amgen: 126,000 shares worth $24.4M.
  • Rock Springs Capital Management added most to AbbVie in Q3 2019, an estimated $25.7M increase.
  • Rock Springs Capital Management's biggest Q3 2019 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $77.4M.
  • Rock Springs Capital Management fully exited Bristol-Myers Squibb in Q3 2019, selling an estimated $47.6M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $2.51B portfolio in Q3 2019.
  • Rock Springs Capital Management opened 11 new positions and closed 7 in Q3 2019.
  • Rock Springs Capital Management's portfolio value fell 9.2% quarter-over-quarter to $2.51B.

Based on Rock Springs Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.